IOX1是一种广谱的2OG氧化酶抑制剂,对于KDM4A/KDM3A和KDM4C/KDM6B/KDM2A/KDM4E的IC50分别为0.6/0.1 μM和0.6 μM/1.6 μM/1.8 μM/2.3 μM。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | KDM1 ↓ ↑ | KDM2 ↓ ↑ | KDM3 ↓ ↑ | KDM4 ↓ ↑ | KDM5 ↓ ↑ | KDM6 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OG-L002 |
+++
LSD1, IC50: 20 nM |
99%+ | |||||||||||||||||
| ORY-1001 |
+++
LSD1, IC50: 20 nM |
98% | |||||||||||||||||
| SP-2509 |
++++
LSD1, IC50: 13 nM |
98+% | |||||||||||||||||
| GSK2879552 2HCl |
+
LSD1, Ki: 1.7 μM |
99%+ | |||||||||||||||||
| T-3775440 HCl |
++++
LSD1, IC50: 2.1 nM |
99% | |||||||||||||||||
| GSK-LSD1 2HCl |
+++
LSD1, IC50: 16 nM |
98% | |||||||||||||||||
| Pulrodemstat benzenesulfonate | ✔ | 99%+ | |||||||||||||||||
| IOX1 |
+
KDM2A, IC50: 1.8 μM |
+++
KDM3A, IC50: 0.1 μM |
++
KDM4E, IC50: 2.3 μM KDM4C, IC50: 0.6 μM |
+
KDM5C, IC50: 19 μM |
+
KDM6B, IC50: 1.6 μM |
99% | |||||||||||||
| PFI-90 | ✔ | 99%+ | |||||||||||||||||
| ML324 |
+
JMJD2, IC50: 920 nM |
99%+ | |||||||||||||||||
| NCGC00244536 |
++++
KDM4, IC50: 10 nM |
99% | |||||||||||||||||
| KDM4D-IN-1 |
++
KDM4D, IC50: 0.41 μM |
99%+ | |||||||||||||||||
| GSK467 |
++++
KDM5B, Ki: 10 nM |
99% | |||||||||||||||||
| GSK-J1 |
+++
JMJD3, IC50: 60 nM |
99%+ | |||||||||||||||||
| (Z)-JIB-04 |
++
JMJD2A, IC50: 1100 nM JMJD2E, IC50: 340 nM |
++
JARID1A, IC50: 230 nM |
++
JMJD3, IC50: 855 nM |
97% | |||||||||||||||
| CPI-455 |
++++
KDM5A, IC50: 10 nM |
++++
KDM5, IC50: 10 nM |
98% | ||||||||||||||||
| JIB-04 |
++
JMJD2D, IC50: 290 nM JMJD2E, IC50: 435 nM |
++
JARID1A, IC50: 230 nM |
++
JMJD3, IC50: 855 nM |
98% | |||||||||||||||
| GSK-J4 HCl |
+++
JMJD3, IC50: 60 nM |
98% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | The Jumonji C domain (JmjC) demethylases belong to the superfamily of FeII and 2-oxoglutarate (2OG) oxygenases. IOX1 is a potent inhibitor against a broad-spectrum of 2OG oxygenases, including non-JmjC 2OG oxygenases, with in vitro IC50 values in the micromolar range. Treatment of HeLa cells with 300μM of IOX1 led to a dose-dependent increase in H3K9me3 fluorescence intensity compared to the DMSO-treated control group. The cellular EC50 value of IOX1 in HeLa cells was 100μM. The amplified luminescent proximity homogeneous assay revealed that the IC50 value of IOX1 for the inhibition of H3K9me3 demethylation activity of isolated KDM4C was 0.6μM. The IC50 values of IOX1 for KDM4E, KDM2A, KDM3A, KDM5C, KDM6B, and PHD2 were 2.3, 1.8, 0.1, 19.0, 1.4, and 33.0μM, respectively.[3] In immunocompetent C57BL/6 mice harboring B16F10 tumors with a volume of about 50 mm3, repetitive intraperitoneal administration of IOX1 (2.5mg/kg) every two days significantly attenuated melanoma expansion at 10 days after treatment.[4] |
| 作用机制 | IOX1 is a potent, broad-spectrum 2OG oxygenase inhibitor with low cell permeability due to its polar C-5 carboxyl group.[3] |
| Concentration | Treated Time | Description | References | |
| AGS cells | 5 μM | 48 h | IOX1 significantly increased the expression of IFN-stimulated genes (ISGs), such as CXCL10, ISG15 and IFNB1 | Adv Sci (Weinh). 2024 Oct;11(40):e2309983. |
| MFC cells | 5 μM | 48 h | IOX1 significantly increased the expression of IFN-stimulated genes (ISGs), such as CXCL10, ISG15 and IFNB1 | Adv Sci (Weinh). 2024 Oct;11(40):e2309983. |
| Mouse keratinocytes | 200 µM | 24 h | To study the effect of IOX-1 on IL-23A expression, results showed that IOX-1 significantly reduced IL-23A expression. | Nat Commun. 2018 Apr 12;9(1):1420. |
| Human keratinocytes | 200 µM | 24 h | To study the effect of IOX-1 on IL-23A expression, results showed that IOX-1 significantly reduced IL-23A expression. | Nat Commun. 2018 Apr 12;9(1):1420. |
| CT26 cells | 5, 25, 50 μM | 24 h | Inhibited P-gp expression and enhanced DOX cytotoxicity | Nat Commun. 2021 Apr 23;12(1):2425. |
| HCT116 cells | 5, 25, 50 μM | 24 h | Inhibited P-gp expression and enhanced DOX cytotoxicity | Nat Commun. 2021 Apr 23;12(1):2425. |
| CT26 cells | 25 μM | 4 h | Enhanced DOX-induced immunogenic cell death (ICD) | Nat Commun. 2021 Apr 23;12(1):2425. |
| HEK293 cells | 100 μM | 24 h | To evaluate the inhibitory effect of IOX1 on histone demethylation, results showed that IOX1 treatment significantly increased the levels of me3Lys and me2Lys. | Anal Chem. 2017 Jan 17;89(2):1299-1306. |
| ESCC cells | 50 µM | 24 h | IOX1 increased H3K9me2 levels and slightly altered H3K27me3 levels, while decreasing the protein expression of KDM3A and KDM6B. | Cell Death Dis. 2020 Dec 14;11(12):1068. |
| ESCC cells | 20 µM | IOX1 decreased the survival fraction of all ESCC cells and increased sensitivity to radiotherapy. | Cell Death Dis. 2020 Dec 14;11(12):1068. | |
| Murine CD4+ T cells | 10 μM and 20 μM | 72 h | To evaluate the effect of IOX1 on Th1 and Th17 cell differentiation, results showed that IOX1 significantly suppressed IL-17 expression but had less effect on IFN-γ expression | EBioMedicine. 2022 Dec;86:104333. |
| Human peripheral blood CD4+ T cells | 25 μM and 100 μM | 5 days | To evaluate the effect of IOX1 on human CD4+ T cell proliferation and differentiation, results showed that IOX1 dose-dependently suppressed IFN-γ and IL-17 expression | EBioMedicine. 2022 Dec;86:104333. |
| A549 | 40 μM | 48 h | IOX1 significantly enhanced the radiosensitivity of A549 cells, significantly increasing γirradiation-induced apoptosis. | Cell Death Dis. 2023 Dec 12;14(12):817. |
| H1299 | 40 μM | 48 h | IOX1 significantly enhanced the radiosensitivity of H1299 cells, significantly increasing γirradiation-induced apoptosis. | Cell Death Dis. 2023 Dec 12;14(12):817. |
| H1975 | 40 μM | 48 h | IOX1 significantly enhanced the radiosensitivity of H1975 cells, significantly increasing γirradiation-induced apoptosis. | Cell Death Dis. 2023 Dec 12;14(12):817. |
| HeLa | 40 μM | 48 h | IOX1 significantly enhanced the radiosensitivity of HeLa cells, significantly increasing γirradiation-induced apoptosis. | Cell Death Dis. 2023 Dec 12;14(12):817. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Renal ischemia-reperfusion injury model | Tail vein injection | 10 mg/kg | Single administration before surgery | IOX1 alleviates renal ischemia-reperfusion injury by increasing m6A methylation and regulating the CCL28/Treg/inflammatory cell axis. | Nat Commun. 2023 Mar 1;14(1):1161 |
| Mice | Subcutaneous xenograft model in nude mice | Intraperitoneal injection | 12.5 mg/kg | Every 2 days, continued treatment | IOX1 significantly suppressed tumor growth, decreased tumor volume, and reduced tumor weight | Adv Sci (Weinh). 2024 Oct;11(40):e2309983. |
| BALB/c mice | S.c. CT26 tumour model | Intravenous injection | 7.5 mg/kg | Every 2 days for 3 times | IPLD significantly inhibited tumour growth and induced immune memory | Nat Commun. 2021 Apr 23;12(1):2425. |
| B10.RIII mice | Experimental autoimmune uveoretinitis (EAU) model | Intraperitoneal injection | 12.5 mg/kg | Twice daily, until peak disease (Day 14) | To evaluate the effect of IOX1 on Th17 cell migration and inflammation in the EAU model, results showed that IOX1 significantly reduced the migration of Th17 cells into the site of inflammation and tissue damage | EBioMedicine. 2022 Dec;86:104333. |
| Nude mice | A549 xenograft model | Injection | 10 mg/kg | Once a day for 6 days | IOX1 significantly suppressed the growth of A549 tumors and enhanced the tumor's sensitivity to radiation. | Cell Death Dis. 2023 Dec 12;14(12):817. |
| Dose | Mice: 2.5 mg/kg[3] (i.p.) |
| Administration | i.p. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
5.29mL 1.06mL 0.53mL |
26.43mL 5.29mL 2.64mL |
52.86mL 10.57mL 5.29mL |
|
| CAS号 | 5852-78-8 |
| 分子式 | C10H7NO3 |
| 分子量 | 189.17 |
| SMILES Code | O=C(C1=C2C=CC=NC2=C(O)C=C1)O |
| MDL No. | MFCD18417145 |
| 别名 | 5-羰基-8-羟基喹啉 |
| 运输 | 蓝冰 |
| InChI Key | JGRPKOGHYBAVMW-UHFFFAOYSA-N |
| Pubchem ID | 459617 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 12 mg/mL(63.44 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1